Business
ERMA: Strong US snus growth offset by NRT write-down; urgent capital needs remain
ERMA: Strong US snus growth offset by NRT write-down; urgent capital needs remain
About this update from Enorama Pharma Ab
Net sales surged to 15.8 MSEK, driven by US snus sales, but losses deepened due to a 17 MSEK NRT write-down. Liquidity is low, with further capital raises needed to fund the ongoing US PMTA process and ensure going concern.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.